These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 37772505)

  • 1. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
    Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.
    Felices M; Lenvik TR; Davis ZB; Miller JS; Vallera DA
    Methods Mol Biol; 2016; 1441():333-46. PubMed ID: 27177679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
    Tay SS; Carol H; Biro M
    Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
    Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
    Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
    Wu Z; Cheung NV
    Pharmacol Ther; 2018 Feb; 182():161-175. PubMed ID: 28834699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.
    Liao B; Tumanut C; Li L; Corper A; Challa D; Chang A; Begum H; Farokhi E; Woods C; Fan X
    MAbs; 2024; 16(1):2381261. PubMed ID: 39048914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
    Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
    MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibody based therapeutics: Strengths and challenges.
    Thakur A; Huang M; Lum LG
    Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
    Zhang M; Lam KP; Xu S
    Front Immunol; 2023; 14():1207276. PubMed ID: 37638058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
    Zorko NA; Ryan CJ
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
    Gleason MK; Verneris MR; Todhunter DA; Zhang B; McCullar V; Zhou SX; Panoskaltsis-Mortari A; Weiner LM; Vallera DA; Miller JS
    Mol Cancer Ther; 2012 Dec; 11(12):2674-84. PubMed ID: 23075808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An engineered NKp46 antibody for construction of multi-specific NK cell engagers.
    Lee RB; Maddineni S; Landry M; Diaz C; Tashfeen A; Yamada-Hunter SA; Mackall CL; Beinat C; Sunwoo JB; Cochran JR
    Protein Eng Des Sel; 2024 Jan; 37():. PubMed ID: 39163262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
    Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
    Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
    Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
    MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approaches to enhance natural killer cell cytotoxicity.
    Stenger TD; Miller JS
    Front Immunol; 2024; 15():1356666. PubMed ID: 38545115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The swinging pendulum of cancer immunotherapy personalization.
    Abraham TS; Snook AE
    Per Med; 2017 May; 14(3):259-270. PubMed ID: 29767586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.
    Shin HG; Yang HR; Yoon A; Lee S
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Killers 2.0: NK cell therapies at the forefront of cancer control.
    Hodgins JJ; Khan ST; Park MM; Auer RC; Ardolino M
    J Clin Invest; 2019 Sep; 129(9):3499-3510. PubMed ID: 31478911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition.
    Fetzko SL; Timothy LD; Parihar R
    Curr Hematol Malig Rep; 2023 Dec; 18(6):264-272. PubMed ID: 37751103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.